Inscription Capital LLC Buys Shares of 1,978 Labcorp Holdings Inc. $LH

Inscription Capital LLC bought a new stake in shares of Labcorp Holdings Inc. (NYSE:LH) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 1,978 shares of the medical research company’s stock, valued at approximately $496,000.

A number of other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Labcorp by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock valued at $2,471,326,000 after purchasing an additional 37,197 shares during the period. Victory Capital Management Inc. lifted its position in Labcorp by 20.0% during the 3rd quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock valued at $756,878,000 after purchasing an additional 440,224 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Labcorp by 10.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock valued at $554,728,000 after purchasing an additional 207,962 shares during the period. Wellington Management Group LLP lifted its position in Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock valued at $604,488,000 after purchasing an additional 289,029 shares during the period. Finally, Bank of America Corp DE lifted its position in Labcorp by 4.0% during the 3rd quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock valued at $208,431,000 after purchasing an additional 27,879 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the sale, the chief executive officer directly owned 80,773 shares of the company’s stock, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the sale, the executive vice president directly owned 30,107 shares of the company’s stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 16,113 shares of company stock valued at $4,547,450 in the last quarter. 0.84% of the stock is owned by company insiders.

Labcorp Stock Performance

Shares of LH stock opened at $259.58 on Wednesday. The stock has a 50-day moving average of $271.64 and a 200-day moving average of $267.63. Labcorp Holdings Inc. has a one year low of $218.76 and a one year high of $293.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. The stock has a market cap of $21.33 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 1.80 and a beta of 1.02.

Labcorp (NYSE:LH) last posted its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. During the same period in the prior year, the business earned $3.45 EPS. Labcorp’s revenue for the quarter was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, sell-side analysts expect that Labcorp Holdings Inc. will post 17.67 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s dividend payout ratio is presently 27.53%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Piper Sandler upped their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen cut Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Robert W. Baird upped their price target on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $307.20.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.